DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 188 filers reported holding DENALI THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 2.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,075,462 | +381.0% | 36,444 | +275.5% | 0.01% | +400.0% |
| Q1 2023 | $223,603 | -62.6% | 9,705 | -54.8% | 0.00% | -66.7% |
| Q4 2022 | $597,553 | -54.0% | 21,487 | -49.3% | 0.00% | -57.1% |
| Q3 2022 | $1,300,000 | -8.1% | 42,356 | -11.9% | 0.01% | 0.0% |
| Q2 2022 | $1,414,000 | +17.5% | 48,058 | +28.5% | 0.01% | 0.0% |
| Q1 2022 | $1,203,000 | +93.4% | 37,389 | +168.2% | 0.01% | +133.3% |
| Q4 2021 | $622,000 | -31.6% | 13,941 | -22.6% | 0.00% | -50.0% |
| Q3 2021 | $909,000 | -43.0% | 18,016 | -35.6% | 0.01% | -50.0% |
| Q1 2021 | $1,596,000 | +35.4% | 27,958 | +98.6% | 0.01% | +20.0% |
| Q4 2020 | $1,179,000 | -72.5% | 14,074 | -88.3% | 0.01% | -72.2% |
| Q3 2020 | $4,295,000 | +1604.4% | 119,879 | +1052.4% | 0.04% | +1100.0% |
| Q2 2020 | $252,000 | – | 10,403 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |